Identifiers | |
---|---|
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H24N4O5 |
Molar mass | 376.413 g·mol−1 |
3D model (JSmol) | |
| |
|
Ro 44-3888 is a non-peptidic, selective and reversible glycoprotein IIb/IIIa inhibitor. It is the active metabolite of sibrafiban.[1] It was being investigated as a treatment for heart conditions, including myocardial infarctions. The development of Ro 44-3888 and sibrafiban was discontinued in 1999 following unfavorable Phase III efficacy data.
See also
References
- ↑ Brennan MP, Cox D, Chubb AJ (2007). "Peptide diversity in drug discovery". In Atta-ur-Rahman, Caldwell GW, Choudhary MI, Player MR (eds.). Frontiers in drug design and discovery. Vol. 3. Saif Zone, Sharjah, United Arab Emirates: Bentham Science Publishers. p. 395-432 (414). ISBN 978-1-60805-201-1.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.